Compare GIC & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIC | DMRA |
|---|---|---|
| Founded | 1949 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1996 | 2020 |
| Metric | GIC | DMRA |
|---|---|---|
| Price | $39.60 | $29.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $43.00 |
| AVG Volume (30 Days) | 119.1K | ★ 306.7K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | 17.09 | ★ 121.48 |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $1,379,100,000.00 | N/A |
| Revenue This Year | $5.72 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | $28.71 | ★ N/A |
| Revenue Growth | ★ 4.80 | N/A |
| 52 Week Low | $26.40 | $16.50 |
| 52 Week High | $40.71 | $34.89 |
| Indicator | GIC | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 68.34 | 46.05 |
| Support Level | $38.16 | $28.16 |
| Resistance Level | $40.71 | $34.23 |
| Average True Range (ATR) | 0.89 | 1.50 |
| MACD | -0.12 | -0.25 |
| Stochastic Oscillator | 62.72 | 4.72 |
Global Industrial Co is a value-added industrial distributor. The company distributes a wide range of industrial and maintenance, repair, and operations (MRO) products to customers across North America, including storage and shelving, safety and security, carts and trucks, HVAC and fans, furniture and decor, material handling, janitorial and facility maintenance, workbenches and shop desks, tools and instruments, plumbing and pumps, office and school supplies, packaging and shipping, lighting and electrical, food service and retail, medical and laboratory, motors and power transmission, building supplies, machining, fasteners and hardware, vehicle maintenance, and raw material.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.